NCT04416282View on ClinicalTrials.gov

Efficacy of Early Terlipressin Plus Albumin Therapy in Comparison to Standard Treatment for HRS-AKI in Acute-on-chronic Liver Failure.

NACompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

June 22, 2020

Primary Completion Date

June 10, 2022

Study Completion Date

June 10, 2022

Conditions
Acute-On-Chronic Liver FailureHepatorenal SyndromeAcute Kidney Injury
Interventions
DRUG

Terlipressin

Injection terlipressin 2 mg/24 hours infusion

BIOLOGICAL

Albumin

i/v albumin 1g/Kg/day

Trial Locations (1)

110070

Institute of Liver & Biliary Sciences, New Delhi

All Listed Sponsors
lead

Institute of Liver and Biliary Sciences, India

OTHER

NCT04416282 - Efficacy of Early Terlipressin Plus Albumin Therapy in Comparison to Standard Treatment for HRS-AKI in Acute-on-chronic Liver Failure. | Biotech Hunter | Biotech Hunter